The immunotherapy known as pembrolizumab appears to be effective in treating malignant mesothelioma, a rare form of lung cancer.
This disease occurs mainly as a result of exposure to asbestos, or what is known as asbestos.
The researchers confirmed that this treatment achieved an initial positive result when used against this rare type of cancer.
Malignant mesothelioma, commonly referred to as mesothelioma, is a rare cancer that originates in the mesothelioma, the thin membrane that forms the lining layer in many body cavities such as the chest, heart, abdomen and most internal organs.
Malignant pleural mesothelioma, which affects the lining of the chest cavity and lungs, accounts for 90% of cases with mesothelioma. Unfortunately, the chances of survival for those infected are very poor.
Pembrolizumab, an FDA-approved monoclonal antibody directed against programmed cell death 1 protein (PD-1), initially received FDA accelerated approval for advanced refractory melanoma in September. 2014 and subsequently received approval to treat several other oncological conditions, many of which are currently in clinical development.
Pembrolizumab, also known as Keytruda, is used to treat cancer by interfering with the growth and spread of cancer cells in the body. Monoclonal antibody.
How to use pembrolizumab ?
Pembrolizumab is given as an injection through a vein (ie, it is an intravenous treatment) for 30 minutes, usually once every 3 weeks or once every 6 weeks. The patient may receive some medications before this injection is given to reduce allergic reactions, and the amount of pembrolizumab that the patient will receive depends on It depends on many factors, including weight and general health, taking into account any other health problems and the type of cancer or condition being treated, all of which will be determined by the doctor, whether the dose and schedule for that dose.
Symptoms of an acute injection reaction that may occur during treatment with pembrolizumab include fever, fainting, chills, shakiness, flushing, difficulty breathing, or dizziness. Tell the patient’s healthcare provider right away if they have any of these symptoms during treatment.
How does pembrolizumab work ?
Pembrolizumab blocks the activity of a molecule called PD-1, a protein that prevents T cells from recognizing and attacking inflamed tissue and cancer cells by blocking the molecule PD-1. T cells can invade melanoma anywhere in the body.
For the treatment of oncological diseases, three classic forms of therapy and their combinations are used :
- surgical excision
Chemotherapy drugs are usually given into the bloodstream, which act throughout the body on all rapidly multiplying cells. By adding various DNA errors, these cells become damaged. Since not only cancer cells are rapidly dividing in the body, but also the cells of the mucous membranes and hair follicles, these tissues are also attacked by chemotherapy.
Surgical excision allows removal of a solid tumor. Here diseased tissue is taken with a margin of safety from healthy tissue. For further histological examination of the tumor, the removed tissue is always pathologically examined. After that, further therapeutic measures can be determined.
In radiation therapy, photon or proton beams are directed at the tumor to be treated. The DNA damage of cancer cells is replaced heterogeneously, depending on the stage of the cell cycle during irradiation. As the radiation passes through more tissues until it reaches the tumor, it can cause discomfort as a side effect, such as radiation dermatitis after breast irradiation or continuity disorder after prostate irradiation.
In addition to the three traditional modalities of treatment, modern methods are well established in everyday clinical practice in the treatment of cancer. These include :
- for immune therapy
- Radiopharmaceutical therapy